New hope for stomach cancer: targeted drug BL-M07D1 enters final trial
NCT ID NCT07152405
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 3 trial tests a new drug called BL-M07D1 against standard chemotherapy in 490 people with HER2-positive advanced stomach or gastroesophageal junction cancer that has worsened after initial treatment. The study aims to see if BL-M07D1 helps people live longer or slows cancer growth. Participants will receive either BL-M07D1 or a doctor-chosen chemotherapy, given by infusion every few weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BL-M07D1 (an antibody-drug conjugate targeting HER2)
What this could lead to
If successful, this could offer a new treatment option for people with HER2-positive advanced stomach cancer whose current therapy has stopped working.
What could go wrong
This is a phase 3 trial, but the drug is still experimental. It may not improve survival or could have side effects like other chemotherapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, China
Contact
-
Harbin Medical University Cancer Hospital
RECRUITINGHarbin, Heilongjiang, China
Contact